Table 1.

Patient overview

	Study Name	# Placebo patients	Age distribution	Males:Females	End Trial R:NR	Early Trial R:NR	Reference
Rheumatoid arthritis	Option	63	x̅ = 52.9, σ = 11.2, min = 24, max = 80	16:47	42:41	25:38	Smolen et al. [15]
	Lithe	111	x̅ = 54.3, σ = 11.5, min = 20, max = 78	23:88	53:58	35:76	Kremer et al. [16]
	Ambition	27	x̅ = 51.4, σ = 13.6, min = 26, max = 82	10:17	18:9	9:18	Jones et al. [17]
	Radiate	53	x̅ = 51.0, σ = 13.1, min = 20, max = 74	12:41	21:32	20:33	Emery et al. [18]
	Toward	110	x̅ = 57.0, σ = 11.0, min = 26, max = 80	34:86	60:50	43:67	Genovese et al. [19]
	TOTAL	364	x̅ = 54.2, σ = 11.9, min = 20, max = 82	95:269	194:170	132:232
Asthma	Lute	31	x̅ = 52.8, σ = 15.5, min = 22, max = 75	11:20	7:24	8:23	Hanania et al. [20]
	Verse	19	x̅ = 56.8, σ = 9.3, min = 39, max = 74	10:9	6:13	5:14	Hanania et al. [20]
	Lavolta 1	187	x̅ = 51.6, σ = 11.8, min = 18, max = 75	70:117	38:149	56:131	Hanania et al. [21]
	Lavolta 2	183	x̅ = 49.5, σ = 12.9, min = 18, max = 74	71:112	42:141	44:139	Hanania et al. [21]
	TOTAL	420	x̅ = 51.0, σ = 12.6, min = 18, max = 75	162:258	93:327	113:307
TOTAL		784	x̅ = 52.5, σ = 12.3, min = 18, max = 82	257:527	287:497	245:539

Demographic information for the 784 patients included in the study. Each patient was enrolled in one of nine clinical trials for the treatment of uncontrolled Asthma or Rheumatoid Arthritis. “End trial” refers to phenotype assignment of response (R) or non-response (NR) at the clinically defined conclusion of the trial. “Early trial” refers to the phenotype being defined as R/NR in the first month of treatment. References are for the original placebo-controlled study publication